Small Biomedical Device Co. Is Ready to Take a Big Step Into Success
Source: Tim Weintraut  (6/8/22)
After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough. More >

Biopharma Co. Meets Primary Endpoints in ARDS Trial
Source: Streetwise Reports  (6/8/22)
MediciNova Inc. shares traded 9% higher after the company released top-line data from its Phase 2 study of MN-166 (ibudilast) in hospitalized COVID-19 patients deemed to be at elevated risk for acute respiratory distress syndrome. In the study, MN-166 demonstrated significant decreases in respiratory failure. More >

FDA Approves Co.'s New Medical Grade Air Hygiene Device
Source: Streetwise Reports  (6/7/22)
Shares of AeroClean Technologies Inc. traded 150% higher after the company reported it received 510k clearance from the U.S. FDA for its Pūrgoâ„¢ medical-grade indoor air purification technology that uses UV-C LEDs to eradicate airborne bacteria, fungi, and viruses, including COVID-19. More >

Approved Drug Shows Promise in Follicular Lymphoma
  (6/6/22)
Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report. More >

FDA Approval of Drug Could Be on the Way
  (6/3/22)
"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection. More >

Bristol Myers to Buy Precision Oncology Co.
Source: Streetwise Reports  (6/3/22)
Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share. More >

Precision Oncology Co. Signs $1.325B Licensing Deal
Source: Streetwise Reports  (6/2/22)
Repare Therapeutics Inc. shares traded more than 50% higher after the company reported it entered into a worldwide license and collaboration agreement with Roche AG for its anti-tumor drug camonsertib (RP-3500). The agreement includes an upfront payment of $125 million and up to an additional $1.2 billion in development, sales and royalties if certain milestones are achieved. More >

Important Data for COVID Drug Candidate Due This Month
  (6/2/22)
The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report. More >

Monkeypox Virus Test Could Yield Revenue for Its Creator
  (5/31/22)
The Utah-based diagnostics firm has multiple shots on goal with this specific molecular test and with its convenient, fast testing platform, both in development, noted an H.C. Wainwright & Co. report. More >

Cancer Patients Have Partial Response With Drug
  (5/28/22)
The developer of this antibody just released the results of its dose evaluation in solid tumors, noted a Wedbush report. More >

Cancer Targeting Drug Better Tolerated Than Others
  (5/27/22)
A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report. More >

50% Revenue Growth Expected This Year for Biopharma Co.
  (5/26/22)
The company is pursuing several strategies to boost revenue, including clinical trials to possibly expand the label of one of its approved dermatological drugs, noted a ROTH Capital Partners report. More >

Trial Shows Colon Cleansing Device to Be Effective
  (5/26/22)
"The positive results could drive physician adoption when scheduling colonoscopies for hard-to-prepare patients going forward," noted an H.C. Wainwright & Co. report. More >

FDA Approves New Skin Resurfacing Device
Source: Streetwise Reports  (5/26/22)
Apyx Medical Corp. shares traded 50% higher after the company reported it received U.S. FDA 510(k) clearance for its Renuvion Dermal Handpiece for use in specific cosmetic dermal resurfacing procedures. More >

Target Price on Drug Co. Suggests Possible Huge Returns
  (5/25/22)
Through H2/22, this biopharma intends to keep advancing its psychedelic drug formulations for major depression, noted a ROTH Capital Partners report. More >

US Biopharma Co. Chooses One Endpoint for Phase 3 Trial
Source: Dr. Thomas Shrader  (5/24/22)
With this strategic decision, the company hopes to increase the chances its dry eye disease drug gets greenlighted, noted a BTIG report. More >

Cannabis Firm Posts Improved Q2 FY22 YOY
  (5/23/22)
Compared to the previous year, the company's overall operating results for the quarter are better, noted a Noble Capital Markets report. More >

Innoviva Buys Remaining Shares in Advanced Antibiotic Co.
Source: Streetwise Reports  (5/23/22)
Shares of Entasis Therapeutics traded 21% higher after the company reported it entered into a definitive merger agreement with Innoviva Inc., whereby Innoviva will acquire all outstanding shares of Entasis that it does not already own for $2.20 per share. More >

H2/22 Slated to Be Catalyst Rich for Pharma Co.
  (5/21/22)
Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that its newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs. More >

US Pharma Co. Granted FDA Approval for IV Smallpox Drug
Source: Streetwise Reports  (5/20/22)
SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox. More >

New Improved Drug Expected to Get FDA Approval Next Month
  (5/20/22)
Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock. More >

Firm Reports Encouraging Trial Results in Cystinosis
  (5/19/22)
New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc. More >

EU Co. Secures Smallpox Vaccine Order to Target Monkeypox
Source: Streetwise Reports  (5/19/22)
Shares of Danish vaccine company Bavarian Nordic A/S traded 70% higher after the company advised that it had secured a contract for its IMVANEX® smallpox vaccine from an undisclosed country in Europe for use in addressing newly confirmed cases of monkeypox. More >

Coverage Launched on Co. in Alzheimer's Drug Space
  (5/17/22)
This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report. More >

Clinical Catalysts for Biotech's Stock On Track for Mid 2022
  (5/15/22)
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report. More >